Autologous cord blood mononuclear cell infusion for the prevention of bronchopulmonary dysplasia in very preterm monozygotic twins: A study protocol for a randomized, placebo-controlled, double-blinded multicenter trial.

Background: Preterm-associated complications remain the main cause of neonatal death. Survivors face the challenges of short- and long-term complications. Among all complications, bronchopulmonary dysplasia (BPD) remains the first important cause of neonatal mortality and morbidity. Current treatment does not address this main preterm complication. Cord blood is regarded as a convenient source of stem cells. The paracrine bioactive factors of stem cells contribute to tissue repair and immune modulation. Our clinical studies and those of others have shown that cord blood cell infusion is both safe and possibly effective in the prevention and treatment of BPD. The therapeutic use of cord blood has emerged as a promising therapy. However, the genetic heterogeneity between control and intervention groups may reduce the comparability especially among small sample trials. The purpose of this study protocol is to investigate the effects of autologous cord blood mononuclear cell (ACBMNC) infusion on the prevention of BPD in very preterm monozygotic twins of less than 32 gestation weeks. Methods: In this prospective, randomized, placebo-controlled, double-blinded multicenter clinical trial, 60 pairs of monozygotic twin preterm neonates of less than 32 weeks admitted to the Neonatal Intensive Care Unit are randomly assigned to receive intravenous ACBMNC infusion (targeted at 5 × 107 cells/kg) or placebo (normal saline) within 24 h after birth in a 1:1 ratio. The primary outcome will be survival without BPD at 36 weeks of postmenstrual age. The secondary outcomes will include the mortality rate, BPD severity, other common preterm complication rates, respiratory support duration, length and cost of hospitalization, and long-term respiratory and neurodevelopmental outcomes during a 2-year follow-up. Furthermore, we will perform single-cell RNA sequencing for cord blood cells and blood cells 3-10 days after intervention and detect whether reactive oxygen species and inflammatory cytokines are present. Conclusion: This will be the first randomized, placebo-controlled, double-blinded trial to evaluate the efficacy of ACBMNC infusion to prevent BPD in monozygotic twin premature infants and investigate the underlying protective mechanisms. The results of this trial will provide valuable clinical evidence for translational application of cord blood cell therapy in very preterm infants.Trial registration: ClinicalTrials.gov, NCT05087498, registered 10/09/2021, https://register.clinicaltrials.gov/prs/app/action/SelectProtocol?sid=S000BAD7&selectaction=Edit&uid=U0002PLA&ts=2&cx=qvyylv.

Multi-feature fusion method for medical image retrieval using wavelet and bag-of-features.

Color, texture, and shape are the common features used for the retrieval systems. However, many medical images have a spot of color information. Therefore, the discriminative texture and shape features should be extracted to obtain a satisfied retrieval result. In order to increase the credibility of the retrieval process, many features can be combined to be used for medical image retrieval. Meanwhile, more features require more processing time, which will decrease the retrieval speed. In this paper, wavelet decomposition is adopted to generate different resolution images. Bag-of-feature, texture, and LBP feature are extracted from three different-level wavelet images. Finally, the similarity measure function is obtained by fusing these three types of features. Experimental results show that the proposed multi-feature fusion method can achieve a higher retrieval accuracy with an acceptable retrieval time.

13N-NH3 versus F-18 FDG in detection of intracranial meningioma: initial report.

PURPOSE: Relatively high Tl-201 uptakes have been reported in all types of meningiomas, and it have been proposed that (201)TlCl SPECT could predict histologic types of meningiomas and differentiate the benign and aggressive meningiomas. Similar to Tl-201, (13)N-(13)NH(4)(+) is an analog of K(+) and could substitute K(+) in some cases. The aim of this study was to evaluate the capacity of PET with (13)N-NH(3) to discriminate meningioma from healthy tissue, and compare with F-18 FDG. METHODS: Eleven patients with the neuroradiologic diagnosis of meningiomas were studied with (13)N-NH(3), and 10 of them were performed with F-18 FDG PET within 3 days. Ten of them were histologically confirmed (6 grade I, 4 grade II), and another one was proved by radiologic (computed tomography and magnetic resonance imaging) and clinical investigation.The PET images were evaluated by semiquantitative analysis using tumor-to-white matter ratio (T/W). RESULTS: (13)N-NH(3) uptake was obviously increased in all 11 meningiomas with a good contrast to the surrounding normal brain tissues. Conversely, F-18 FDG uptake was decreased in comparison with the contralateral side in all 7 patients with grade I meningiomas and moderately increased in the remaining patient with grade II meningioma. The T/W ratio of (13)N-NH(3) was higher than that of F-18 FDG (7.03 ± 1.62 vs. 1.44 ± 0.57, P < 0.005). T/W of (13)N-NH(3) uptake was not useful for differentiating benign (Grade I) from atypical (Grade II) meningiomas (P = 0.88), whereas the T/W ratio of F-18 FDG uptake was better than that of N-NH3 for differentiating benign from malignant meningiomas (P = 0.037). CONCLUSIONS: These preliminary results suggest that (13)N-NH(3) has relatively greater uptake in meningiomas in comparison with F-18 FDG. Clinical applications of (13)N-NH(3) PET for grading and follow-up of meningiomas need to be assessed in further studies.

Usefulness of (13)N-NH (3) PET in the evaluation of brain lesions that are hypometabolic on (18)F-FDG PET.

We investigated the usefulness of (13)N-NH(3) PET in characterizing brain lesions which show hypometabolism on (18)F-FDG PET. (13)N-NH(3) PET was performed in 18 patients with brain lesions (in 14 for initial diagnosis and in 4 for detection of astrocytoma recurrence) that showed hypometabolism compared with normal brain tissue on (18)F-FDG PET. The diagnoses were ten gliomas, one metastatic tumor, one dysembryoplastic neuroepithelial tumor (DNT), and six non-neoplastic lesions (including three cases of radiation necrosis, two cases of encephalitic foci, and one ischemic lesion). Diagnosis was verified by histopathological examination in 13 patients or was established by clinical follow-up and additional investigations in the remainder. Seven of 12 brain tumors (58%, sensitivity) showed increased (13)N-NH(3) uptake despite hypometabolism on (18)F-FDG PET. The three low-grade gliomas, one metastatic tumor, and one DNT showed decreased (13)N-NH(3) uptake. The mean (±SD) uptake ratio of (13)N-NH(3) was significantly higher than that of (18)F-FDG (1.24 ± 0.57 vs. 0.67 ± 0.21, P < 0.01) in the tumors. By contrast, all six non-neoplastic lesions showed decreased (13)N-NH(3) uptake (100% specificity). The mean (±SD) uptake ratio of (18)F-FDG and (13)N-NH(3) in the non-neoplastic lesions was 0.68 ± 0.15 and 0.70 ± 0.19, respectively, and there was no significant difference between them (P > 0.05). The mean (±SD) uptake ratio of (13)N-NH(3) in the tumors was significantly higher than that in the non-neoplastic lesions (1.24 ± 0.53 vs. 0.70 ± 0.19, P < 0.05). The preliminary results of this study suggest that (13)N-NH(3) PET may be helpful to detect and differentiate brain tumors which show hypometabolism on (18)F-FDG PET from non-neoplastic lesions with high specificity, especially for cerebral astrocytomas, but the sensitivity is relatively limited.